NCT06280534View on ClinicalTrials.gov

Safety, Tolerability Phase Ia Study of XT1061 in Single and Multiple Doses in Healthy Subjects

PHASE1RecruitingINTERVENTIONAL
Enrollment

128

Participants

Timeline

Start Date

July 18, 2023

Primary Completion Date

February 29, 2024

Study Completion Date

March 31, 2024

Conditions
Chronic Hepatitis b
Interventions
DRUG

Test drug XT1061 capsules and placebo,Single dose group

Eight people took capsules of the test drug XT1061 and two people took a placebo.

DRUG

Test drug XT1061 capsules and placebo，Multiple dosing group

D1-D7 were administered under fasting conditions for 7 consecutive days, of which D1-D6 were administered BID and D7 was administered once in the morning under fasting conditions only.Eight people took capsules of the test drug XT1061 and two people took a placebo.

DRUG

Test drug XT1061 capsules and placebo，Food Impact Group

Eight people in group A took the test drug XT1061 capsules and two people took placebo, and all eight people in group B took the test drug XT1061 capsules.

Trial Locations (1)

Unknown

RECRUITING

The First Hospital of Jilin University, Jilin

All Listed Sponsors
lead

Xi'an Xintong Pharmaceutical Research Co.,Ltd.

OTHER